[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337417-105":59,"doc-detail-337417-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","lifetime-risks-of-second-primary-malignancies-after-pediatric-hodgkin-lymphoma-and-non-hodgkin-lymphoma","Lifetime risks of second primary malignancies after pediatric Hodgkin lymphoma and non-Hodgkin lymphoma","","Objectives: quantify lifelong risk of second primary malignancy (SPM) among childhood survivors of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) and characterize incidence patterns. Methods: used US-wide population-based cancer registry data. Results: survivors showed increased SPM risk (HL 4.74-fold; NHL 3.40-fold) with rising cumulative incidence over 40 years (22.2% HL; 12.6% NHL). Among 6805 cases, 6.36% developed SPM, especially second breast and thyroid cancers. Gender, lymphoma subtype, and radiotherapy were linked; chemotherapy accelerated timing without increasing incidence. Conclusions: pediatric lymphoma survivors face high lifetime SPM risk, warranting early signs monitoring.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/lifetime-risks-of-second-primary-malignancies-after-pediatric-hodgkin-lymphoma-and-non-hodgkin-lymphoma/337417/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/lifetime-risks-of-second-primary-malignancies-after-pediatric-hodgkin-lymphoma-and-non-hodgkin-lymphoma/337417.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":46},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address about pediatric lymphoma survivors?","Question",{"text":112,"@type":113},"It estimates lifetime risk of second primary malignancy (SPM) after pediatric Hodgkin lymphoma and non-Hodgkin lymphoma and describes incidence patterns over long follow-up.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was SPM risk measured in this research?",{"text":117,"@type":113},"Using US-wide population-based cancer registry data, the study quantified SPM risk and analyzed incidence patterns among children diagnosed with lymphoma.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors were significantly associated with developing SPM?",{"text":121,"@type":113},"Competing risk analysis showed significant associations with gender, lymphoma subtype, and radiotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337417,1790131820,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":46,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Journal of Cancer Research and Clinical Oncology (2024) 150:41  \n[https://doi.org/10.1007/s00432-023-05583-4](https://doi.org/10.1007/s00432-023-05583-4)  \nLifetime risks of second primary malignancies after pediatric Hodgkin lymphoma and non‑Hodgkin lymphoma  \nLaduona Wang1 · Yue Zheng1 · Ren Luo1 · Kai Kang1 · Gabriele Niedermann2,3,4 · Ailin Zhao5 · Yijun Wu1  \nReceived: 13 November 2023 / Accepted: 7 December 2023 / Published online: 27 January 2024 © The Author(s) 2024  \nAbstract  \nObjectives Survivors after pediatric Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are with lifetime risk for second primary malignancy (SPM) . This necessitates a thorough analysis to better understand the potential long-term health implications for these individuals.  \nMethods We used a US-wide population-based cancer registry data to quantify the SPM risk and identify its incidence patterns among pediatric lymphoma patients.  \nResults We observed 4 .74-fold (95% CI 4 .27–5.25) and 3 .40-fold (95% CI 2 .78–4. 10) increased risks of SPM in survivors after pediatric HL and NHL, respectively. Through over 40 years’ follow-up, the cumulative incidence of SPM for pediatric lymphoma was persistently increasing, and here we firstly report the high 40-year cumulative incidence rates of SPM, 22.2% for HL and 12.6% for NHL, suggesting that SPM accounts for a great proportion of deaths among survivors. Of 6805 pediatric lymphomas, 462 (6.36%) developed a SPM, especially second breast and thyroid cancer, followed by hematologic neoplasms including leukemia and NHL. The competing risk analysis demonstrated gender, lymphoma subtype and radiotherapy were significantly associated with SPM. Different risk patterns of SPM were identified between pediatric HL and NHL. Chemotherapy accelerated SPM development but did not increase its incidence risk.  \nConclusion Overall, patients after pediatric lymphoma can be with high lifetime risk of SPM, and more attention should be paid to SPM-related signs for early detection and intervention.  \nKeywords Pediatric lymphoma · Second primary malignancy · Radiotherapy · Chemotherapy  \nLaduona Wang, Yue Zheng, Ren Luo contributed equally as first authors.  \n* Ailin Zhao [irenez20@outlook.com](irenez20@outlook.com)  \n* Yijun Wu [wuyj01029@wchscu.cn](wuyj01029@wchscu.cn)  \n1 Cancer Center, West China Hospital, Sichuan University, Chengdu, China  \n2 Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany  \n3 German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany  \n4 German Cancer Research Center (DKFZ), Heidelberg, Germany  \n5 Department of Hematology, West China Hospital, Sichuan University, Chengdu, China  \nIntroduction  \nWith the advent of novel treatments, the life expectancy of lymphoma patients, including pediatric cases, has been significantly extended. However, this progress has given rise to a new and serious concern—the development of second primary malignancies (SPMs) . In adult patients, especially those with specific lymphoma subtypes, previous studies have explored the relationships between SPMs and factors such as genetic vulnerability, family history, immunodeficiency, environmental exposure, and various treatment modalities (Chattopadhyay et al. 2020 ; Chien et al. 2015 ; Chowdhry et al. 2015 ; Hemminki et al. 2003 ; Joelsson et al. 2022 ; Sud et al. 2017) . Yet, there remains a noticeable gap in the research literature when it comes to a comprehensive investigation into pediatric lymphoma survivors, encompassing all subtypes of Hodgkin lymphoma (HL) and nonHodgkin lymphoma (NHL) .  \nThe National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program, which aggregates data from nearly one-third of the U.S. cancer patient population, provides an invaluable resource for filling this void. Our study, based on SEER database registries, sought to identify patients who received their initial primary lymphoma diagnosis at the age ","cbCaitqCgejkHR5E","https://ap.wps.com/l/cbCaitqCgejkHR5E","pdf",1484862,"English","# Abstract\n## Objectives\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Methods\n## Data source\n## Patient enrollment","[{\"question\":\"What question does the study address about pediatric lymphoma survivors?\",\"answer\":\"It estimates lifetime risk of second primary malignancy (SPM) after pediatric Hodgkin lymphoma and non-Hodgkin lymphoma and describes incidence patterns over long follow-up.\"},{\"question\":\"How was SPM risk measured in this research?\",\"answer\":\"Using US-wide population-based cancer registry data, the study quantified SPM risk and analyzed incidence patterns among children diagnosed with lymphoma.\"},{\"question\":\"Which factors were significantly associated with developing SPM?\",\"answer\":\"Competing risk analysis showed significant associations with gender, lymphoma subtype, and radiotherapy.\"}]","Lifetime risks of second primary malignancies after pediatric Hodgkin lymphoma and non-Hodgkin lymphoma | PDF",1790019053,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2fa9b4e45801653d34199220b973a33.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e292c4acc28860617121d71ba25a9a6d.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8fd48a561c7f342fbd41fa2b5f2e798.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c00ec06330cd49d62e4bb1144818f40a.webp",980,1301]